Test Price
2,800 AED✅ Home Collection Available
JAK2 Mutation Analysis (Exons 12, 14, 16) by Next-Generation Sequencing (NGS) in UAE | 2800 AED
Executive Summary & Core Metrics
This advanced molecular test precisely identifies JAK2 mutations in exons 12, 14 and 16 using NGS, delivering 99.9% diagnostic sensitivity. The service includes hospital-grade home collection, VIP phlebotomy, cold-chain transport under ISO 9001:2015 (Cert: INT/EGQ/2509DA/3139), and direct insurance billing verification via WhatsApp. Results are interpreted with expert post-test clinical guidance. Fully compliant with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields.
Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO Accredited Processing.
Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection (Available daily from 8 AM to 11 PM).
Clinical Guidance: Telephonic Post-Test Clinical Guidance in Result Interpretation.
Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731.
Test Overview & Methodology
The JAK2 Mutation Analysis by NGS precisely identifies somatic mutations in exons 12, 14, and 16 of the JAK2 gene, critical for diagnosing Philadelphia-negative myeloproliferative neoplasms (MPNs) such as polycythemia vera, essential thrombocythemia, and primary myelofibrosis. This advanced genetic test provides high sensitivity and is used to guide treatment and assess thrombotic risk.
| Feature | Our Test (NGS Exon 12,14,16) | Closest Alternative (Sanger / Limited Panel) |
|---|---|---|
| Precision | >99.9% sensitivity for low-frequency variants | ~95% sensitivity, may miss minor clones |
| Methodology | Next-Generation Sequencing (Illumina® platform), allele-specific analysis | Sanger sequencing or ARMS-PCR, limited exon coverage |
| Turnaround Time | 3–4 weeks, with integrated genetic counseling | 4–6 weeks, often without counseling support |
Physician Insight & Safety Protocols
"As a consultant medical genetics specialist, I understand that facing a possible myeloproliferative neoplasm can be daunting. This test provides vital molecular evidence to confirm the diagnosis and tailor therapy, but results must be correlated with full blood counts and clinical symptoms. A negative JAK2 mutation does not rule out all MPNs; other driver mutations may be present."
— Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
Important Medication Advisory
Medication Warning
Do not discontinue any prescribed blood thinners, hydroxyurea, or chemotherapy without consulting your doctor. Abrupt cessation may increase thrombosis risk.
Exclusion Criteria & ER Red Flags
Exclusion Criteria
- Individuals under 18 years require parental consent and a pre-test genetic counseling session before sample collection (Federal Decree-Law No. 4 of 2016 on Medical Liability).
- Recent blood transfusion (within 14 days) or severe hemolysis may compromise DNA quality; reschedule the draw.
- Pregnancy: genetic counseling advised; test may proceed but requires specialist referral and informed consent.
- Emergency Red Flags: Sudden severe headache, blurred vision, chest pain, or unilateral leg swelling could indicate acute thrombosis—seek immediate medical attention.
Patient FAQ & Clinical Guidance
1. What does the JAK2 NGS test detect, and why is it important?
The JAK2 NGS test detects mutations in exons 12, 14, and 16 to accurately diagnose myeloproliferative neoplasms and guide treatment. Mutations in JAK2, especially V617F (exon 14), are found in over 95% of polycythemia vera and 50-60% of essential thrombocythemia and primary myelofibrosis. The NGS method identifies both common and rare variants with high sensitivity, enabling precise classification and risk stratification for thrombotic events.
2. How should I prepare for the JAK2 blood test, and what are the sample requirements?
No fasting or medication changes are required; a simple blood draw or buccal swab is collected for optimal DNA extraction. Our home collection team uses ISO-certified cold chain transport to maintain sample integrity, and you can provide whole blood, extracted DNA, or a dried blood spot on an FTA card. A genetic counseling session will be arranged to review your pedigree and explain the implications.
3. Is the JAK2 test covered by insurance in the UAE?
Many UAE insurers cover JAK2 mutation testing when medically necessary; direct billing verification is available via WhatsApp. Our team contacts your insurer to confirm coverage for the 2800 AED, and we handle documentation for DHA-regulated facilities. For insurers requiring pre-authorization, we assist with the clinical justification letter.
4. What if I have a negative result? Does that rule out MPNs?
A negative JAK2 mutation result does not completely rule out all myeloproliferative neoplasms. Other driver mutations (e.g., CALR, MPL) can be present. Your physician will correlate results with blood counts and clinical findings. Additional testing may be recommended based on your overall clinical picture.
UAE Regulatory & Data Privacy Adherence
Trust and Compliance
This test is performed at DNA Labs UAE, a DHA-licensed facility (License No. 1143) in Dubai Healthcare City. We strictly adhere to:
- Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) – ensuring secure handling and storage of your genetic data.
- Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields – governing electronic health records and telemedicine.
- Federal Decree-Law No. 4 of 2016 on Medical Liability – covering clinical safety, informed consent, and patient rights.
Our ISO 9001:2015 quality management system (Cert: INT/EGQ/2509DA/3139) ensures consistent, high-standard diagnostic processes.
Clinical & Logistical Metadata
| Test Name | JAK2 Mutation Analysis (Exons 12, 14, 16) by Next-Generation Sequencing (NGS) |
| Price (AED) | 2800 |
| Turnaround Time | 3–4 weeks |
| Sample Type / Matrix | Whole blood (EDTA), buccal swab, or extracted DNA |
| Methodology Used | Targeted Next-Generation Sequencing (Illumina® platform), allele-specific analysis |
| ICD-10-CM Code | D45, D47.3, D47.1 |
| LOINC Code | 82939-2 |
| DHA Facility License & Laboratory Address | License No. 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians